{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:12:19Z","timestamp":1774084339307,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T00:00:00Z","timestamp":1255737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s11060-009-0034-y","type":"journal-article","created":{"date-parts":[[2009,10,16]],"date-time":"2009-10-16T05:15:56Z","timestamp":1255670156000},"page":"401-407","source":"Crossref","is-referenced-by-count":37,"title":["The role of salvage reirradiation for malignant gliomas that progress on bevacizumab"],"prefix":"10.1007","volume":"97","author":[{"given":"Roy G.","family":"Torcuator","sequence":"first","affiliation":[]},{"given":"Ravneet","family":"Thind","sequence":"additional","affiliation":[]},{"given":"Mehul","family":"Patel","sequence":"additional","affiliation":[]},{"given":"Y. S.","family":"Mohan","sequence":"additional","affiliation":[]},{"given":"Joseph","family":"Anderson","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Doyle","sequence":"additional","affiliation":[]},{"given":"Samuel","family":"Ryu","sequence":"additional","affiliation":[]},{"given":"Rajan","family":"Jain","sequence":"additional","affiliation":[]},{"given":"Lonni","family":"Schultz","sequence":"additional","affiliation":[]},{"given":"Mark","family":"Rosenblum","sequence":"additional","affiliation":[]},{"given":"Tom","family":"Mikkelsen","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,10,17]]},"reference":[{"key":"34_CR1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1212\/01.wnl.0000304121.57857.38","volume":"70","author":"AD Norden","year":"2008","unstructured":"Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas. Efficacy, toxicity, and patterns of recurrence. Neurology 70:779\u2013787","journal-title":"Neurology"},{"issue":"5","key":"34_CR2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1215\/15228517-2009-006","volume":"11","author":"E Quant","year":"2009","unstructured":"Quant E, Norden A, Drappatz J, Muzikansky A, Doherty L, LaFrankie D, Ciampa A, Kesari K, Wen PY (2009) Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 11(5):550\u2013555. doi: 10.1215\/15228517-2009-006","journal-title":"Neuro Oncol"},{"key":"34_CR3","first-page":"9963","volume":"23","author":"S Combs","year":"2005","unstructured":"Combs S, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:9963\u20139969","journal-title":"J Clin Oncol"},{"key":"34_CR4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11060-008-9752-9","volume":"92","author":"M Patel","year":"2009","unstructured":"Patel M, Siddiqui F, Jian-Yue J, Mikkelsen T, Rosenblum M, Movsas B, Ryu S (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol 92:185\u2013191","journal-title":"J Neurooncol"},{"key":"34_CR5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280","journal-title":"J Clin Oncol"},{"key":"34_CR6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1118\/1.1842911","volume":"32","author":"JY Jin","year":"2005","unstructured":"Jin JY, Yin FF, Ryu S, Ajlouni M, Kim JH (2005) Dosimetric study using different leaf-width MLCs for treatment planning of dynamic conformal arcs and intensity-modulated radiosurgery. Med Phys 32:405\u2013411. doi: 10.1118\/1.1842911","journal-title":"Med Phys"},{"key":"34_CR7","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1118\/1.2392605","volume":"33","author":"JY Jin","year":"2006","unstructured":"Jin JY, Ryu S, Faber K, Mikkelsen T, Chen Q, Li S, Movsas B (2006) 2D\/3D image fusion for accurate target localization and evaluation of a mask based stereotactic system in fractionated stereotactic radiotherapy of cranial lesions. Med Phys 33:4557\u20134566. doi: 10.1118\/1.2392605","journal-title":"Med Phys"},{"issue":"1","key":"34_CR8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijrobp.2008.10.043","volume":"75","author":"PH Gutin","year":"2008","unstructured":"Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey L (2008) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75(1):156\u2013163","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"34_CR9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-008-9718-y","volume":"91","author":"RM Zuniga","year":"2009","unstructured":"Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329\u2013336","journal-title":"J Neurooncol"},{"key":"34_CR10","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"J Vredenburgh","year":"2007","unstructured":"Vredenburgh J, Desjardins A, Herndon J II, Marcello J, Reardon D, Quinn J, Rich J, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner D, Friedman A, Friedman H (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722\u20134729","journal-title":"J Clin Oncol"},{"key":"34_CR11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"T Kreisl","year":"2009","unstructured":"Kreisl T, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman J, Camphausen K, Park J, Albert P, Fine H (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740\u2013745","journal-title":"J Clin Oncol"},{"key":"34_CR12","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ijrobp.2007.11.068","volume":"71","author":"A Lai","year":"2008","unstructured":"Lai A, Filka E, McGibbon B, Nghiemphu P, Graham C, Yong W, Paul MP, Liau L, Bergsneider M, Pope W, Selch M, Cloughesy T (2008) PHASE II pilot study of bevacizumab in combination temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372\u20131380","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"34_CR13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.05.062","volume":"72","author":"A Narayana","year":"2008","unstructured":"Narayana A, Golfinos J, Fisache I, Raza S (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383\u2013389","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"34_CR14","first-page":"723","volume":"46","author":"L Milas","year":"1986","unstructured":"Milas L, Ito H, Hunter N, Jones S, Peters LJ (1986) Retardation of tumor growth in mice caused by radiation-induced injury of tumor bed stroma: dependency on tumor type. Cancer Res 46:723\u2013727","journal-title":"Cancer Res"},{"key":"34_CR15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccr.2007.11.032","volume":"13","author":"GO Ahn","year":"2008","unstructured":"Ahn GO, Brown JM (2008) Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13:193\u2013205","journal-title":"Cancer Cell"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-009-0034-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-009-0034-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-009-0034-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:19:28Z","timestamp":1559362768000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-009-0034-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,17]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1007\/s11060-009-0034-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,17]]}}}